Trial Profile
Phase 2 trial of TAS-102 plus bevacizumab in patients with advanced/recurrent colorectal cancer who had previously received on oxaliplatin, irinotecan and fluoropyrimidine
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2021
Price :
$35
*
At a glance
- Drugs Tipiracil/trifluridine (Primary) ; Bevacizumab
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 01 Apr 2021 Results (n=19) published in the Anticancer Research
- 22 Feb 2017 New trial record